Navigation Links
Pros and Cons of Adaptive Designs: A Leisurely Conversation Between a Clinician and Two Statisticians, New Webinar Hosted by Xtalks
Date:12/17/2013

Toronto, Canada (PRWEB) December 17, 2013

This webinar will discuss adaptive designs for phase I, phase II and phase III clinical trials in oncology and will take the form of a debate between two statisticians trying to meet the requirements of an oncologist. The panel will include Dr. Marc Buyse, Founder and Chairman of IDDI, Dr. Tomasz Burzykowski, Vice President of Research for IDDI, and Dr. Everardo Saad, Scientific Director and Chairman for Dendrix and Senior Oncology Consultant for IDDI.

The pros and cons of various adaptive designs will be discussed. Topics will include continual reassessment methods for phase I trials, adaptive Bayesian designs for phase III trials, adaptive sample size increases and adaptive enrichment of phase III trials.

For more information on this webinar or to register, visit: http://xtalks.com/Pros-and-Cons-of-Adaptive-Designs.ashx.

To learn more about IDDI, visit http://www.iddi.com.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran (416) 977-6555 ext 224
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11425544.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
2. Elsevier Introduces Adaptive Study Solution for Improved Learning and Memory Retention for Nursing and Health Professions
3. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
4. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
5. PI Releases High Power Piezo Amplifier to Drive Adaptive Structures, Fast Tool Servos, Vibration Cancellation Systems – Model E-482
6. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
7. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
8. “The New Health Conversation” to Premiere on PBS
9. GMO Answers Invites Consumers to Join the Online Conversation during GMO Awareness Month in October
10. Plant Biotechnology Companies Begin New Conversation about GMOs and How our Food is Grown
11. Intrinsically disordered proteins: A conversation with Rohit Pappu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare ... training and support program, Sonalink™ remote monitoring. The inaugural launch of this new ... February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare ...
(Date:2/10/2016)... BC (PRWEB) , ... February 09, 2016 , ... ... design services and current winner of the Highest Overall Customer Rating Award ... in all of its business units across the USA, Canada, Mexico and China. ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... innovations on its free and validated Electronic Data Capture (EDC) system ClinCaptureand its ... in Clinical Trials West Coast 2016 Conference in San Mateo, California on February ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, ... immunotherapies for cancer, announced that its lead ... European Commission as an orphan medicinal product ... deadliest form of glioma, strikes approximately 25,000 ... EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):